Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.95 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.95 |
| ▸ | CES2 | O00748 | 2/20 | 0.60 |
| ▸ | CES1 | P23141 | 2/20 | 0.60 |
| ▸ | SRC | P12931 | 2/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mandelic Acid SCHEMBL5202802 | 1.00 | LMNA (0.95) | LMNAMAPK1CES2CES1SRC | |
| Mandelic Acid SCHEMBL21647917 | 0.97 | LMNA (1.00) | LMNAMAPK1CES2CES1SRC | |
| Mandelic Acid SCHEMBL5313046 | 0.97 | LMNA (1.00) | LMNAMAPK1CES2CES1SRC | |
| Mandelic Acid SCHEMBL165161 | 0.97 | LMNA (1.00) | LMNAMAPK1CES2CES1SRC | |
| Mandelic Acid SCHEMBL255601 | 0.97 | LMNA (1.00) | LMNAMAPK1CES2CES1SRC | |
| Mandelic Acid SCHEMBL1050 | 0.97 | LMNA (1.00) | LMNAMAPK1CES2CES1SRC | |
| Mandelic Acid SCHEMBL29777368 | 0.97 | LMNA (1.00) | LMNAMAPK1CES2CES1SRC | |
| Mandelic Acid SCHEMBL1680817 | 0.95 | LMNA (0.95) | LMNAMAPK1CES2CES1SRC | |
| Mandelic Acid SCHEMBL3934174 | 0.95 | LMNA (0.95) | LMNAMAPK1CES2CES1SRC | |
| Mandelic Acid SCHEMBL6439484 | 0.95 | LMNA (0.95) | LMNAMAPK1CES2CES1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110746242-A | Preparation process of graphene and titanium element synergistic micro-nano biological bacterial fertilizer | 福州钧鼎生物科技有限公司 | 2020-02-04 | — | — | CN | claimed |
| WO-1996009345-A1 | USE OF ZIRCONIUM SALTS TO IMPROVE THE SURFACE SIZING EFFICIENCY IN PAPER MAKING | HOPTON TECHNOLOGIES, INC. (US) | 1996-03-28 | — | — | WO | claimed |
| US-5460645-A | Blend of hydroxylated polymer, carboxylated polymer, group four compound and water | AKZO NOBEL N.V. (NL) | 1995-10-24 | — | — | US | claimed |
| CN-110746242-A | Preparation process of graphene and titanium element synergistic micro-nano biological bacterial fertilizer | 福州钧鼎生物科技有限公司 | 2020-02-04 | — | — | CN | disclosed |
| CN-104034722-B | Content of material assay method in a kind of complex silicon carbide | 江苏永钢集团有限公司 | 2016-11-02 | — | — | CN | disclosed |
| CN-100378093-C | Process for the preparation of an optically pure or optically concentrated sulphoxide compound comprising amorphous esomeprazole and its salts | REDDY LAB (IN) | 2008-04-02 | — | — | CN | disclosed |
| EP-1515963-B1 | A PROCESS FOR PREPARATION OF OPTICALLY PURE OR OPTICALLY ENRICHED SULFOXIDE COMPOUNDS, INCLUDING AMORPHOUS ESOMEPRAZOLE AND SALTS THEREOF | REDDYS LAB LTD DR (IN) | 2007-02-14 | — | — | EP | disclosed |
| US-7169793-B2 | Process for preparation of optically pure or optically enriched sulfoxide compounds, including amorphous esomeprazole and salts thereof | DR. REDDY'S LABORATORIES LIMITED (IN) | 2007-01-30 | — | — | US | disclosed |
| CN-1665805-A | Process for the preparation of an optically pure or optically concentrated sulphoxide compound comprising amorphous esomeprazole and its salts | REDDY LAB (IN) | 2005-09-07 | — | — | CN | disclosed |
| EP-1515963-A2 | A PROCESS FOR PREPARATION OF OPTICALLY PURE OR OPTICALLY ENRICHED SULFOXIDE COMPOUNDS, INCLUDING AMORPHOUS ESOMEPRAZOLE AND SALTS THEREOF | Dr. Reddy's Laboratories Ltd. (IN) | 2005-03-23 | — | — | EP | disclosed |
| US-20040077869-A1 | Process for preparation of optically pure or optically enriched sulfoxide compounds, including amorphous esomeprazole and salts thereof | DR. REDDY'S LABORATORIES LIMITED | 2004-04-22 | — | — | US | disclosed |
| WO-2004002982-A2 | A PROCESS FOR PREPARATION OF OPTICALLY PURE OR OPTICALLY ENRICHED SULFOXIDE COMPOUNDS, INCLUDING AMORPHOUS ESOMEPRAZOLE AND SALTS THEREOF | DR. REDDY'S LABORATORIES LIMITED (IN) | 2004-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077869-A1 | Process for preparation of optically pure or optically enriched sulfoxide compounds, including amorphous esomeprazole and salts thereof | RPS26, RPS6, RPS27 | LMNA 4482/4885MAPK1 1365/4885CES2 3407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.